Analyzed by medical agent experts, combined with the development of related industries and the research of foreign marketing models, it is believed that pharmaceutical investment will not withdraw from the historical stage of medical marketing, but the investment promotion model will be gradually improved and developed in practice. Pharmaceutical investment promotion companies must adjust their ideas, strategies, personnel, products, sales models, channel strategies, etc. in order to make a wonderful visit to the post-new medical reform era. In the view of pharmaceutical investment professionals, the success of investment promotion products for pharmaceutical companies must first involve products or services that attract dealers' attention.
Moreover, medical agent experts believe that the investment model will not die, which is determined by the development characteristics of the entire industry. Although individual agents will gradually reduce under the constraints of the policy, there will be new business entities that need to seek cooperation. Therefore, the investment model of pharmaceutical companies will not disappear, but only need to keep pace with the times. As a mode of operation with low investment and high returns in the pharmaceutical industry, investment promotion has always been a favorite of many companies. However, due to the various drawbacks and problems of pharmaceutical investment products, whether investment promotion has a future or not, how to attract businesses to expand and strengthen the company has always been discussed by many companies.
With the increasing homogenization of many products today, pharmaceutical investment promotion companies must base their innovation on product development, create humanized advantages in the operation process, and realize optimized combination of business, product and price, and create a new market structure. The process of drug investment promotion is also a process of self-advocacy. Under the background of reform and opening up, China's pharmaceutical market is facing a social environment of information explosion, media proliferation, product homogeneity, and diversified consumer markets, which greatly dissipates consumption. The attention of the person.
At present, dealers are becoming increasingly rational, and “big strokes†have become a thing of the past. It has been difficult to produce tens of millions or billions of dollars of products through the use of pharmaceutical investment products. The bigger the hope, the greater the disappointment, and the greater expectations for investment. In the end, the ultimate cause of injury is still the company itself. As for those who constantly develop products, they are constantly requesting approval for signs, constantly advertising and attracting investment, and taking pharmaceutical investment as the main source of profits, and they will fight for a place to change. Investment professionals, the result of which, ultimately, can only be a faster demise.
In addition, drug investment experts believe that in light of the different policy guidance of the new medical reform on the three terminals in the current pharmaceutical investment industry, companies that are determined to conduct product investment and agency in different channels will have to profoundly study policy directions and the resulting changes in the entire channel. The impact on business operations, such as in clinical channels. At present, there are still a large number of individual agents who control the active use of clinical channels, and because there is a long-term foundation of cooperation, such cooperation will not change in a certain period of time in the future.
Moreover, medical agent experts believe that the investment model will not die, which is determined by the development characteristics of the entire industry. Although individual agents will gradually reduce under the constraints of the policy, there will be new business entities that need to seek cooperation. Therefore, the investment model of pharmaceutical companies will not disappear, but only need to keep pace with the times. As a mode of operation with low investment and high returns in the pharmaceutical industry, investment promotion has always been a favorite of many companies. However, due to the various drawbacks and problems of pharmaceutical investment products, whether investment promotion has a future or not, how to attract businesses to expand and strengthen the company has always been discussed by many companies.
With the increasing homogenization of many products today, pharmaceutical investment promotion companies must base their innovation on product development, create humanized advantages in the operation process, and realize optimized combination of business, product and price, and create a new market structure. The process of drug investment promotion is also a process of self-advocacy. Under the background of reform and opening up, China's pharmaceutical market is facing a social environment of information explosion, media proliferation, product homogeneity, and diversified consumer markets, which greatly dissipates consumption. The attention of the person.
At present, dealers are becoming increasingly rational, and “big strokes†have become a thing of the past. It has been difficult to produce tens of millions or billions of dollars of products through the use of pharmaceutical investment products. The bigger the hope, the greater the disappointment, and the greater expectations for investment. In the end, the ultimate cause of injury is still the company itself. As for those who constantly develop products, they are constantly requesting approval for signs, constantly advertising and attracting investment, and taking pharmaceutical investment as the main source of profits, and they will fight for a place to change. Investment professionals, the result of which, ultimately, can only be a faster demise.
In addition, drug investment experts believe that in light of the different policy guidance of the new medical reform on the three terminals in the current pharmaceutical investment industry, companies that are determined to conduct product investment and agency in different channels will have to profoundly study policy directions and the resulting changes in the entire channel. The impact on business operations, such as in clinical channels. At present, there are still a large number of individual agents who control the active use of clinical channels, and because there is a long-term foundation of cooperation, such cooperation will not change in a certain period of time in the future.
Bottle Pepper Powder,Small Amount Pepper Powder,Small Package Pepper Powder,Pepper Powder Small Package
jiangmen city hongsing food co., ltd. , https://www.jmhongsing.com